Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral erythromycin for Dowling-Meara epidermolysis bullosa simplex
2010-024428-10Phase 2
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erythromycin in epidermolysis bullosa simplex (EBS), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoints: Responder rate based on reduction in new cutaneous blisters and Average number of new cutaneous blisters per day.
02
Drugs
erythromycin
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on 2010-024428-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024428-10.